# A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

> **NCT01770613** · PHASE2 · WITHDRAWN · sponsor: **Stemedica Cell Technologies, Inc.**

## Conditions studied

- ST Segment Elevation Myocardial Infarction (STEMI)
- Allogeneic Mesenchymal Bone Marrow Cells

## Interventions

- **BIOLOGICAL:** Stem cells

## Key facts

- **NCT ID:** NCT01770613
- **Lead sponsor:** Stemedica Cell Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-02
- **Primary completion:** 2016-05
- **Final completion:** 2017-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Corporate business decision, may consider different subject population
- **Last updated:** 2017-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770613, "A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01770613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*